In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

Explore Laveran's groundbreaking discovery of the malaria parasite and its lasting impact on infectious disease research and ...

Developed by British drugmaker GSK, RTS,S/AS01E in 2021 became the first malaria vaccine to be recommended by the World ...

Plasmodium falciparum causes malaria in humans by multiplying first in the liver cells and then in red blood cells. Merozoites or daughter parasites are released as the host cells are destroyed to ...

Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Calcium is essential for the correct functioning of the cell and requires regulation to avoid high concentrations causing cell death. Calcium ions are important for cell signaling as the binding of ...

A new, comprehensive map of all the genes essential for blood infections in Plasmodium knowlesi (P. knowlesi), a parasite that causes malaria in humans, has been generated. The map contains the most ...

Immune modulation of Plasmodium vivax and P. falciparum gametocytes occurs over the course of erythrocytic infection. The response is linked to proliferative and inflammatory responses, which may be ...

This is a preview. Log in through your library . Abstract Plasmodium inui (Halberstaedter and von Prowazek, 1907), a malarial parasite of Old World monkeys that occurs in isolated pockets throughout ...